Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference on June 22, 2020, at 2:00 p.m. PT (5:00 p.m. ET). CEO Kevin Gorman will lead the presentation. The live event will be webcast and available on the company's website, with a replay accessible one hour after the event and archived for approximately one month. Neurocrine focuses on developing treatments for neurological and endocrine disorders, with a portfolio that includes FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease.

News Market Reaction – NBIX

+3.09%

+3.09% Session move

In the trading session that priced this news, NBIX gained 3.09%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, June 15, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-bank-of-america-securities-2020-napa-biopharma-conference-301076985.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences present at the Bank of America Securities 2020 Napa Biopharma Conference?

Neurocrine Biosciences will present on June 22, 2020, at 2:00 p.m. PT (5:00 p.m. ET).

Who will present at the Neurocrine Biosciences conference?

CEO Kevin Gorman will present at the conference.

How can I access the Neurocrine Biosciences presentation?

The presentation can be accessed live via webcast on the Neurocrine website.

Will there be a replay available for the Neurocrine Biosciences presentation?

Yes, a replay will be available approximately one hour after the event and will be archived for about one month.

What is Neurocrine Biosciences known for?

Neurocrine Biosciences specializes in developing treatments for neurological, endocrine, and psychiatric disorders.